ONO-2952

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 528601

CAS#: 895169-20-7

Description: ONO-2952 is a peripheral benzodiazepine receptor antagonist potentially for the treatment of irritable bowel syndrome.

Chemical Structure

img
ONO-2952
CAS# 895169-20-7
Instruction

Theoretical Analysis

MedKoo Cat#: 528601
Name: ONO-2952
CAS#: 895169-20-7
Chemical Formula: C22H20ClFN2O2
Exact Mass: 398.12
Molecular Weight: 398.860
Elemental Analysis: C, 66.25; H, 5.05; Cl, 8.89; F, 4.76; N, 7.02; O, 8.02

Price and Availability

This product is not in stock, which may be available by custom synthesis. For cost-effective reason, minimum order is 1g (price is usually high, lead time is 2~3 months, depending on the technical challenge). Quote less than 1g will not be provided. To request quote, please email to sales @medkoo.com or click below button.
Note: Price will be listed if it is available in the future.

Request quote for custom synthesis

Synonym: ONO-2952; ONO2952; ONO 2952

IUPAC/Chemical Name: (S)-1-(1'-(4-chloro-2-methoxyphenyl)-5'-fluoro-1',9'-dihydrospiro[cyclopropane-1,4'-pyrido[3,4-b]indol]-2'(3'H)-yl)ethan-1-one

InChi Key: ZBQMTQGDBFZUBG-NRFANRHFSA-N

InChi Code: CC(N(C[15:S=N]HC[19]()=CC=C(Cl)C=C@19OC)CC[2](C[7]()=C(@15)NC[14]=C@8C(F)=CC=C@14)CC@3)=O

SMILES Code: CC(N([C@H]1C2=CC=C(Cl)C=C2OC)CC3(C4=C1NC5=C4C(F)=CC=C5)CC3)=O

Appearance: Solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: Soluble in DMSO

Shelf Life: >2 years if stored properly

Drug Formulation: This drug may be formulated in DMSO

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.9001

More Info:

Biological target:
In vitro activity:
In vivo activity:

Preparing Stock Solutions

The following data is based on the product molecular weight 398.86 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol:
In vitro protocol:
In vivo protocol:

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.
=
x
x
g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Dilution Calculator

Calculate the dilution required to prepare a stock solution.
x
=
x

1: Frankle WG, Narendran R, Wood AT, Suto F, Himes ML, Kobayashi M, Ohno T, Yamauchi A, Mitsui K, Duffy K, Bruce M. Brain translocator protein occupancy by ONO-2952 in healthy adults: A Phase 1 PET study using [(11) C]PBR28. Synapse. 2017 Feb 28. doi: 10.1002/syn.21970. [Epub ahead of print] PubMed PMID: 28245513.

2: Mitsui K, Niwa T, Kawahara Y, Morimoto N, Ohmoto K, Kato M, Yamaura Y, Yoshimoto N, Suna H, Katsumata S. Anti-stress effects of ONO-2952, a novel translocator protein 18 kDa antagonist, in rats. Neuropharmacology. 2015 Dec;99:51-66. doi: 10.1016/j.neuropharm.2015.07.011. Epub 2015 Jul 17. PubMed PMID: 26189762.

3: Suto F, Wood AT, Kobayashi M, Komaba J, Duffy K, Bruce M. Safety, Tolerability, and Pharmacokinetic Profile of the Novel Translocator Protein 18 kDa Antagonist ONO-2952 in Healthy Volunteers. Clin Ther. 2015 Sep;37(9):2071-84. doi: 10.1016/j.clinthera.2015.07.010. Epub 2015 Aug 4. PubMed PMID: 26249232.

4: Mitsui K, Morimoto N, Niwa T, Yamaura Y, Ohba H, Tsukada H, Katsumata S. Quantification of ONO-2952 Occupancy of 18-kDaTranslocator Protein in Conscious Monkey Brains using Positron Emission Tomography. J Pharmacol Exp Ther. 2017 Mar;360(3):457-465. doi: 10.1124/jpet.116.238568. Epub 2016 Dec 16. PubMed PMID: 27986860.

5: Whitehead WE, Duffy K, Sharpe J, Nabata T, Bruce M. Randomised clinical trial: exploratory phase 2 study of ONO-2952 in diarrhoea-predominant irritable bowel syndrome. Aliment Pharmacol Ther. 2017 Jan;45(1):14-26. doi: 10.1111/apt.13839. Epub 2016 Nov 7. PubMed PMID: 27910150.

6: Nee J, Lembo A. Editorial: ONO-2952 in irritable bowel syndrome with diarrhoea. Aliment Pharmacol Ther. 2017 Apr;45(7):1004-1005. doi: 10.1111/apt.13920. PubMed PMID: 28256084.

7: Whitehead WE, Duffy K, Sharpe J, Nabata T, Bruce M. Editorial: ONO-2952 in irritable bowel syndrome with diarrhoea - authors' reply. Aliment Pharmacol Ther. 2017 Apr;45(7):1005. doi: 10.1111/apt.13957. PubMed PMID: 28256085.